Takeda UK has received approval from the Scottish Medicines Consortium (SMC) for its Adcetris (brentuximab vedotin) for restricted use within NHS Scotland, in order to treat adult patients with CD30+ relapsed or refractory Hodgkin’s lymphoma (HL).

SMC evaluated cancer treatment Adcetris through its ultra-orphan decision making framework, which is a new assessment process.

Dundee’s Ninewells Hospital consultant haematologist Dr David Meiklejohn said: "It is great news that eligible patients in Scotland now have access to this innovative treatment option, particularly as patients at this stage of disease can be very difficult to treat effectively with standard treatments."

The approval has been granted to use Adcetris for the treatment of patients with CD30+ relapsed or HL, following an autologous stem cell transplant (ASCT) or following at least two previous therapies, when ASCT or multi-agent chemotherapy is not an option.

"It is great news that eligible patients in Scotland now have access to this innovative treatment option."

The European Medicines Agency (EMA) has also granted approval for brentuximab vedotin to treat adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

In a vital phase II trial, brentuximab vedotin has reached primary end point of objective response rate (ORR) in 75% of patients, while a complete remission (CR) is currently around 33%.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lymphoma Association chief executive Jonathan Pearce said: "The Lymphoma Association wants everyone affected by lymphoma to have the best possible treatment and care, so we’re very pleased that the Scottish Medicines Consortium has listened to our advice and is making this treatment option available to those people with Hodgkin’s lymphoma who face limited treatment options."

Image: Nodular lymphocyte predominant Hodgkin lymphoma. Photo: courtesy of Humpath.